Oxford BioMedica PLC (OXBDF)

[georgejjl]

John Dawson to retire from Oxford Biomedica

Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the Company. Accordingly, the Board has initiated a formal search for a successor.

Dr. Roch Doliveux, Chairman of Oxford Biomedica, commented: “John has provided more than 13 years of dedicated service and leadership to Oxford Biomedica and, on behalf of the Board and all of our staff, we thank him wholeheartedly. His successful career with the Company was underlined very recently by a much-deserved CBE awarded for services to UK Life Science. Under his leadership, together with the strong senior executive team, Oxford Biomedica has grown into an industry leader in lentiviral vectors, delivered multiple partnerships and successfully manufactured life-saving COVID-19 vaccine, all due to the expertise and robustness of the Company’s management team. We have commenced a formal process to appoint a successor who will lead the Group through its next phase of growth whilst also ensuring the Company remains fully focussed on the execution of its strategy of delivering life changing gene therapies to patients.”

Good luck and GOD bless,

[georgejjl]

AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says

https://www.cnn.com/2021/03/22/health/astrazeneca-vaccine-efficacy-us-based-clinical-trial/index.html

Good luck and GOD bless,

[georgejjl]

WHO expert group recommends use of AstraZeneca vaccine

https://apnews.com/article/who-experts-astrazeneca-vaccine-385626cd46e68d430db783b284401428

Good luck and GOD bless,

[georgejjl]

AstraZeneca’s (Oxford BioMedica's) vaccine is poised to become the leader in most of the world

https://www.yahoo.com/tech/m/c1c9947e-593c-332a-ac5b-b505f7dfab93/astrazeneca%E2%80%99s-vaccine-is.html

Good luck and GOD bless,

[georgejjl]

WHP completes viral vector manufacturing centre for Oxford Biomedica

The centre is being used for the worldwide manufacture and distribution of the COVID-19 vaccine by AstraZeneca

https://www.globenewswire.com/news-release/2020/12/30/2151646/0/en/Oxford-Biomedica-notes-AstraZeneca-s-COVID-19-vaccine-has-been-authorised-for-emergency-supply-in-the-UK.html

Good luck and GOD bless,

[georgejjl]

Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK

https://www.globenewswire.com/news-release/2020/12/30/2151646/0/en/Oxford-Biomedica-notes-AstraZeneca-s-COVID-19-vaccine-has-been-authorised-for-emergency-supply-in-the-UK.html

Good luck and GOD bless,

[georgejjl]

John Dawson named Executive of the Year for Companies <$10bn at the Annual Scrip Awards 2020
-Ends-

Oxford, UK – 3 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, John Dawson, Chief Executive Officer of Oxford Biomedica, was named Executive of the Year in the category for Companies with a market cap <$10 billion at the 16th Annual Scrip Awards 2020.

This award recognises Oxford Biomedica’s achievements from June 2019 up to the end of May 2020, taking into account the Company’s efforts on the Lentivector® platform and subsequent partnership agreements, which more than doubled in the period from nine to nineteen, including a deal with Juno Therapeutics, a Bristol-Myers Squibb company, the extension of the commercial supply agreement with Novartis for a further five years to work on six programmes, and R&D collaboration with Santen to develop gene therapy products inherited retinal disease.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “It is a huge honour to accept this award on behalf of everyone at Oxford Biomedica and this is a true testament to the dedication and hard work demonstrated by everyone at the Company. We’ve collectively won this award for our efforts on our Lentivector® platform and deals including Juno Therapeutics, a Bristol-Myers Squibb company, and the Novartis extension. This award is by far the biggest recognition that Oxford Biomedica has received for its achievements in driving gene therapy forward for patients, and as a leader in the space. Congratulations to the other nominees on their work this year, and thank you to Scrip for recognising Oxford Biomedica.”

Good luck and GOD bless,

[georgejjl]

FDA allows AstraZeneca’s COVID-19 vaccine trial to resume in US

https://www.fox2detroit.com/news/fda-allows-astrazenecas-covid-19-vaccine-trial-to-resume-in-us

Of course this is the Oxford vaccine.

Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-supply-agreement-astrazeneca-expand-manufacturing

Good luck and GOD bless,

[georgejjl]

Oxford University Covid-19 vaccine trials resume

https://www.yahoo.com/news/oxford-university-resumes-vaccine-trial-135100184.html

Good luck and GOD bless,

[georgejjl]

Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oxford, UK – 1 September, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed an 18 month supply agreement under a three year Master Supply and Development Agreement (“the Agreement”) with AstraZeneca UK Ltd (“AstraZeneca”) for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222. The Parties may extend the supply period for AZD1222 by a further 18 months into 2022 and 2023 by mutual agreement.

Under the terms of the Agreement, AstraZeneca will pay Oxford Biomedica £15million upfront as a capacity reservation fee. Subject to satisfactory scale up of manufacturing capacity and continuation of the vaccine programme, Oxford Biomedica expects to receive additional revenue in excess of £35million plus certain materials costs for the manufacture of multiple large-scale batches of AZD1222 until the end of 2021.

As part of the Agreement, Oxford Biomedica will reserve capacity for AstraZeneca in up to three manufacturing suites in the Group’s new 7,800 m2 commercial manufacturing centre, Oxbox, for an initial 18 month period. This new GMP facility is suitable for manufacturing viral vectored vaccines and gene therapy vectors up to 1,000 litre scale. As part of Oxford Biomedica’s previously announced partnership with the UK’s Vaccine Manufacturing Innovation Centre (VMIC) two new manufacturing suites within Oxbox will become operational in the next two months, significantly earlier than originally planned by the Group.

While this Agreement means the Group has dedicated multiple new manufacturing suites to this critical project, importantly, Oxford Biomedica does not expect any impact to the Groups current partnerships or ability to secure and support additional new partnerships in the cell and gene therapy field.

This agreement builds on the supply agreement between the companies announced on 28th May, which related exclusively to manufacture of AZD1222 at 200L scale and associated process development.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “We have been working hard with AstraZeneca and other partners to establish GMP manufacturing of AZD1222 at scale, and we are therefore very pleased to extend our current partnership to include large-scale manufacturing of the vaccine candidate, AZD1222. Our previously announced partnership with the UK’s Vaccine Manufacturing Innovation Centre (VMIC) has supported our ability to make additional facilities available for this supply agreement. We look forward to continuing to work with AstraZeneca to rapidly contribute to the global effort to support the large-scale manufacturing of AZD1222 to ensure that the vaccine candidate is available if and when it is approved by Regulatory Authorities.”

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-supply-agreement-astrazeneca-expand-manufacturing

Good luck and GOD bless,

[georgejjl]

Oxford coronavirus vaccine induces strong immune response

In the Oxford study, the T cell response was noted within 14 days of receiving the vaccine. Immunity was detected for at least 56 days after getting the shot. It's unclear how long that will last.

https://www.yahoo.com/news/oxford-coronavirus-vaccine-induces-strong-135700376.html

Good luck and GOD bless,

[georgejjl]

Safety and Immunogenicity of Novel 5T4 Viral Vectored Vaccination Regimens in Early Stage Prostate Cancer: A Phase I Clinical Trial
Federica Cappuccini 1, Richard Bryant 2 3, Emily Pollock 1, Lucy Carter 1, Clare Verrill 2 4, Julianne Hollidge 2, Ian Poulton 1, Megan Baker 1, Celia Mitton 1, Andrea Baines 1, Armin Meier 5, Guenter Schmidt 5, Richard Harrop 6, Andrew Protheroe 7, Ruth MacPherson 8, Steven Kennish 9, Susan Morgan 10, Selena Vigano 11, Pedro J Romero 11, Thomas Evans 12, James Catto 13, Freddie Hamdy 2 3, Adrian V S Hill # 1, Irina Redchenko # 14

Affiliations
1Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK.
2Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.
3Department of Urology, Churchill Hospital, Oxford, UK.
4Oxford NIHR Biomedical Research Centre, Oxford University, Oxford, UK.
5Definiens AG, Munchen, Bayern, Germany.
6Oxford Biomedica Plc, Oxford, UK.
7Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.
8Department of Radiology, Churchill Hospital, Oxford, UK.
9Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
10Department of Pathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
11Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
12Vaccitech UK Limited, Oxford, UK.
13Academic Urology Unit, The University of Sheffield, Sheffield, UK.
14Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK [e-mail].
#Contributed equally.
PMID: 32591433 PMCID: PMC7319775 DOI: 10.1136/jitc-2020-000928

Abstract
Background: Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity.

Methods: In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early-stage PCa and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T-cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate-specific antigen (PSA) change, and assessment of phenotype and functionality of antigen-specific T cells.

Results: The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T-cell responses were measured in blood by ex vivo IFN-? ELISpot and were detected in the majority of patients with a mean level in responders of 198 spot-forming cells per million peripheral blood mononuclear cells. Flow cytometry analysis demonstrated the presence of both CD8+ and CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumor-infiltrating lymphocytes were isolated from post-treatment prostate tissue. Some of the patients had a transient PSA rise 2-8 weeks following vaccination, possibly indicating an inflammatory response in the target organ.

Conclusions: An excellent safety profile and T-cell responses elicited in the circulation and also detected in the prostate gland support the evaluation of the ChAdOx1-MVA 5T4 vaccine in efficacy trials. It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab.

Trial registration: The trial was registered with the U.S. National Institutes of Health (NIH) Clinical Trials Registry (ClinicalTrials.gov identifier NCT02390063).

Read more at the following link

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319775/

Good luck and GOD bless,

[georgejjl]

Oxford Biomedica snags manufacturing equipment to ramp up production of COVID-19 vaccine

Oxford Biomedica and AstraZeneca reached a deal in late May to produce "multiple batches" of the university's vaccine. (Getty)

In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca's manufacturing partners has struck a deal for new equipment.

Oxford Biomedica has inked a five-year deal with the U.K.'s Vaccines Manufacturing and Innovation Centre (VMIC) to build out the CDMO's Oxbox facility to help produce doses of the university's adenovirus-based COVID-19 vaccine.

As part of their deal, VMIC will supply manufacturing equipment for two suites at Oxford Biomedica's 84,000-square-foot Oxbox facility in Oxford, U.K., the CDMO said. The suites will be dedicated to producing Oxford's vaccine, AZD1222, but can also be used to manufacture other viral vector vaccines.

BLOG
State-of-the-art is not just a state of mind. It’s how we operate. AMRI has the next generation in sterile pre-filled syringe technology.
Follow our multi-part blog series on PFS technology to learn more!
LEARN MORE
In return, Oxford Biomedica will provide VMRI with "training and technical assistance" for its staff to scale up manufacturing of viral vector vaccines at its new facility at the Harwell Science and Innovation Campus at Oxford scheduled to open in mid-2021.

The manufacturing supply agreement will help Oxford Biomedica begin churning out doses of Oxford's vaccine candidate––which is currently in phase 2/3 trials in the U.K.––beginning this summer.

RELATED: AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal

Late last month, Oxford and British drugmaker AstraZeneca agreed to a one-year deal covering "multiple batches" of the university's vaccine as part of a consortium aimed at speeding production of the shot.

As part of the agreement, AstraZeneca received access to the OxBox facility with the goal of supplying clinical and commercial doses through 2020 with the possibility of expansion in the future.

AstraZeneca and the university agreed to tie up in April, with the drugmaker taking on commercialization and large-scale manufacturing of the school's vaccine, which was developed by Oxford’s Jenner Institute.

RELATED: AstraZeneca unveils massive $750M deal in effort to produce billions of COVID-19 shots

As Oxford Biomedica aims to ramp up its own manufacturing, AstraZeneca recently secured a massive tie-up to bring billions of doses of AZD1222 on the market in the coming years.

Last week, the British pharma inked a $750 million deal with the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance to manufacture and distribute 300 million doses of Oxford's vaccine by the end of 2020, the drugmaker said Thursday.

AZ also agreed to a licensing deal with the Serum Institute of India to provide 1 billion doses of the vaccine to low- and middle-income countries, with the goal of 400 million produced by year's end. In total, the deals bring AstraZeneca's overall supply capacity for Oxford's vaccine to more than 2 billion doses per year, the drugmaker said.

https://www.fiercepharma.com/manufacturing/oxford-biomedica-reaches-manufacturing-equipment-deal-to-ramp-up-production-covid-19

Good luck and GOD bless,

[georgejjl]

AstraZeneca agrees to make COVID-19 vaccine for Europe
European COVID-19 vaccine due by end of 2020

LONDON — Pharma giant AstraZeneca struck a deal Saturday with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of an experimental COVID-19 vaccine, as efforts to boost manufacturing capacity continue at pace.

The alliance, which was forged by Germany, France, Italy and the Netherlands to speed up production of a vaccine, is set to take delivery of the vaccine being tested by the University of Oxford by the end of 2020. The agreement with AstraZeneca also aims to make the vaccine available to other European countries that wish to take part.


The cost is expected to be offset by funding from the governments.

“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,’’ AstraZeneca CEO Pascal Soriot said. “With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.''

The agreement is the latest in a series to make the vaccine — even though it is not certain it will work. But so desperate is the need that scaling up of manufacturing continues despite the risk.

The Anglo-Swedish company recently completed similar agreements with Britain, the United States the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance for 700 million doses. A license also has been agreed with the Serum Institute of India for another 1 billion doses.

The vaccine was developed by Oxford University’s Jenner Institute, working with the Oxford Vaccine Group.

Testing of the experimental COVID-19 vaccine began in healthy volunteers in Britain in April with over 1,000 people aged 18 to 55. Another round with 10,000 volunteers began last month.

Other companies, including Moderna and Sanofi, are racing to develop and produce a vaccine against the new coronavirus, a step experts say will be crucial to allowing countries to ease their lockdowns and restrictions on public life.

https://www.foxbusiness.com/markets/astrazeneca-agrees-to-make-covid-19-vaccine-for-europe

Good luck and GOD bless,

[georgejjl]

AstraZeneca Approaches Gilead About Potential Merger

https://www.bloomberg.com/news/articles/2020-06-07/astrazeneca-is-said-to-approach-gilead-about-potential-merger

Will Oxford BioMedica next?

Good luck and GOD bless,

[georgejjl]

AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine — and it could be ready by September

https://www.cnbc.com/2020/06/04/astrazeneca-is-set-to-make-two-billion-doses-of-a-coronavirus-vaccine.html

Good luck and GOD bless,

[georgejjl]

AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal

https://www.fiercepharma.com/manufacturing/astrazeneca-oxford-biomedica-agree-to-1-year-tie-up-to-produce-covid-19-vaccine

Good luck and GOD bless,

[georgejjl]

Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oxford, UK – 28 May, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca UK Ltd (“AstraZeneca”). The Agreement relates to the GMP manufacture of the adenovirus vector based COVID-19 vaccine candidate, AZD1222, which recently entered clinical trials at multiple sites in the UK. Oxford Biomedica is working alongside AstraZeneca and other manufacturing organisations to provide large scale manufacturing capacity for this vaccine candidate.

As part of the Clinical & Commercial Supply Agreement, AstraZeneca will have access to Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre Oxbox, located in Oxford, UK. In April 2020 Oxford Biomedica announced that it had joined a consortium including the Jenner Institute in relation to the potential for large scale manufacture of AZD1222. On 30 April 2020 AstraZeneca and Oxford University subsequently announced an agreement to enable global development, manufacturing and distribution of the vaccine.

The initial agreement requires Oxford Biomedica to provide AstraZeneca with multiple batches of vaccine, the majority of which are expected to be produced throughout 2020. The production will be from one of the Group’s recently approved GMP suites in Oxbox. The Commercial Supply agreement may be extended further depending on the progression of the programme.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “We are proud to be a part of the manufacturing consortium working with the Jenner Institute at University of Oxford, for the early manufacturing and scale up of this viral vector based candidate for COVID-19. Following the recent announcement of an agreement between the University of Oxford and AstraZeneca, we are very pleased to be one of AstraZeneca’s global network of manufacturing partners, and look forward to them being the third company to have rapid access to our specialised manufacturing capacity for this vaccine candidate at Oxbox”.

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-clinical-commercial-supply-agreement-astrazeneca

Good luck and GOD bless,

[georgejjl]

The Oxford COVID-19 vaccine is 'progressing very well,' according to the lead scientists, who said 10,000 more people would be inoculated

https://www.businessinsider.com/oxford-vaccine-progressing-very-well-10000-injected-in-uk-2020-5

Good luck and GOD bless,

[georgejjl]

U.S. to invest $1.2 billion to secure potential coronavirus vaccine from AstraZeneca, Oxford University (Oxford BioMedica)
Published: May 21, 2020 at 8:31 a.m. ET
By Denise Roland

Government to bankroll human trial and ramp-up of manufacturing capacity as part of ‘Operation Warp Speed,’ hoping to get doses in October 2020

https://www.marketwatch.com/story/us-to-invest-12-billion-to-secure-potential-coronavirus-vaccine-from-astrazeneca-oxford-university-2020-05-21-8103313

Good luck and GOD bless,

[georgejjl]

U.S. to invest $1.2 billion to secure potential coronavirus vaccine from AstraZeneca, Oxford University (Oxford BioMedica)
Published: May 21, 2020 at 8:31 a.m. ET
By Denise Roland

Government to bankroll human trial and ramp-up of manufacturing capacity as part of ‘Operation Warp Speed,’ hoping to get doses in October 2020

https://www.marketwatch.com/story/us-to-invest-12-billion-to-secure-potential-coronavirus-vaccine-from-astrazeneca-oxford-university-2020-05-21-8103313

Good luck and GOD bless,

[georgejjl]

AstraZeneca Aims for 30 Million U.K. Vaccine Doses by September

U.K. will be first to get access to vaccine under development
Plan to open vaccine center near Oxford comes a year early

https://www.bloomberg.com/news/articles/2020-05-17/astrazeneca-aims-for-30-million-u-k-vaccine-doses-by-september

Good luck and GOD bless,

[marcusl2]

HTTps://www.bloomberg.com/profile/company/1300802D:US

[marcusl2]

Nine Ten Capital Management LLC Buys , Oxford BioMedica PLC

https://www.gurufocus.com/news/1139080/nine-ten-capital-management-llc-buys-par-technology-corp-oxford-biomedica-plc-agilysys-inc-sells-instructure-inc-techtarget-inc

[georgejjl]

Monkey trial of Oxford vaccine shows encouraging results

https://www.cbsnews.com/news/oxford-university-monkey-trial-of-coronavirus-vaccine-shows-encouraging-results/

Good luck and GOD bless,

[georgejjl]

In April the Group has joined a Consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine candidate for COVID-19 called ChAdOx1 nCoV-19. AstraZeneca subsequently entered into an agreement with Oxford University for the global development and distribution of the vaccine on 30th April. While the potential impact on the Group is currently uncertain, should clinical trials be successful the Group will provide access to its large scale GMP manufacturing facilities including Oxbox to support the manufacturing scale up for Oxford University and AstraZeneca.

https://www.oxfordbiomedica.co.uk/news-media/press-release/preliminary-results-year-ended-31-december-2019

Good luck and GOD bless,

[georgejjl]

Oxford Biomedica bags MHRA nod for two manufacturing suites

https://roxettbranscome.wordpress.com/2020/05/13/oxford-biomedica-bags-mhra-nod-for-two-manufacturing-suites/

Good luck and GOD bless,

[marcusl2]

John Dawson, Chief Executive Officer of Oxford Biomedica, said:

"We are delighted that despite COVID-19 the MHRA has been able to complete the inspection and sign off of the two suites and supporting areas within our world class Oxbox manufacturing facility. This not only secures facilities for our current and future cell and gene therapy partner programmes but also potentially provides access to the Oxford COVID-19 Vaccine Consortium for production of vaccine should the clinical trials prove to be successful."

https://uk.advfn.com/stock-market/london/oxford-biomedica-OXB/share-news/Oxford-Biomedica-PLC-OXB-receives-approval-for-fir/82441882

[georgejjl]

Emily Whitehead past, present and FUTURE

https://www.oxfordbiomedica.co.uk/videos/emily-whitehead-first-child-be-enrolled-ctl019

https://www.wearecentralpa.com/news/local-news/cancer-survivor-runs-5k-to-save-lives/

https://www.facebook.com/EWhiteheadFdn/?hc_ref=ARThtfdkO6mapSmBj9Zyjbu-ic9zwsi-gqqcKBXQtZhBnhmhh0Nja74Plp4pm1ry21c&fref=nf&__tn__=kC-R

Good luck and GOD bless,

[georgejjl]

Oxford scientist says its vaccine is making headway, could show efficacy by June

https://www.nbcnews.com/politics/meet-the-press/oxford-scientist-says-its-vaccine-making-headway-could-show-efficacy-n1198946

Good luck and GOD bless,

[georgejjl]

Bill Gates says the world would need as many as 14 billion doses of a coronavirus vaccine to stop the virus

https://www.yahoo.com/news/bill-gates-says-world-many-190805965.html

Good luck and GOD bless,

[georgejjl]

Coronavirus vaccine update: How far along is the research? | COVID-19 Special

Good luck and GOD bless,

[georgejjl]

Bill Gates says the world will need 7 billion vaccine doses to end COVID-19 pandemic

https://www.yahoo.com/finance/news/bill-gates-says-world-7-190044086.html

Good luck and GOD bless,

[georgejjl]

The Jenner Institute at Oxford University made the headlines this week as it could have a few million doses ready as early as September.

A US study showed that monkeys which were administered the Oxford vaccine survived exposure to the virus and were healthy four weeks after receiving the jab.

Although immunity in monkeys does not necessarily ensure the same will happen in humans, the results are encouraging as the team prepare to test 6,000 people by the end of May.

The university also signed a deal with AstraZeneca PLC (LON:AZN), which will produce and distribute the vaccine if and when it is approved, on a not-for-profit basis for the duration of the coronavirus pandemic.

Biotech firm Oxford Biomedica PLC (LON:OXB) is also involved in the production.

Ironically, flattening the curve of coronavirus cases in the UK comes as a challenge.

“We’re the only people in the country who want the number of new infections to stay up for another few weeks, so we can test our vaccine,” Prof. Adrian Hill, the Jenner Institute’s director, told the New York Times.

Researchers are not allowed to infect test participants with a serious disease: the only way to prove whether a vaccine is successful is to have trials in an area where the virus is widespread.

https://www.proactiveinvestors.co.uk/companies/news/918330/the-four-coronavirus-vaccine-candidates-to-watch-918330.html

Good luck and GOD bless,

[georgejjl]

AstraZeneca enters deal to manufacture University of Oxford's potential COVID-19 vaccine


https://www.firstwordpharma.com/node/1720124

Good luck and GOD bless,

[georgejjl]

In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead

The institute last week began a Phase I clinical trial involving 1,100 people. Crucially, next month it will begin a combined Phase II and Phase III trial involving another 5,000. Unlike any other vaccine project now underway, that trial is designed to prove effectiveness as well as safety.

https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html?mod=article_inline

Good luck and GOD bless,

[georgejjl]

Good News on Oxford Vaccine Is Bright Spot in Somber Covid-19 Landscape

MilliporeSigma, a division of the German company Merck KGaA (MRK.Germany), said on April 14 that it would work on manufacturing the vaccine with Jenner. Oxford Biomedica (OXB) is also working on manufacturing the vaccine.

https://www.barrons.com/articles/good-news-on-oxford-vaccine-is-bright-spot-in-somber-covid-19-landscape-51588084298

Good luck and GOD bless,

[georgejjl]

6 monkeys given an experimental coronavirus vaccine from Oxford did not catch COVID-19 after heavy exposure, raising hopes for a human vaccine

https://www.yahoo.com/news/6-monkeys-given-experimental-coronavirus-094138199.html

Good luck and GOD bless,

[georgejjl]

University of Oxford coronavirus vaccine trial aims to have 500 people in testing by mid-May

https://techcrunch.com/2020/04/17/university-of-oxford-coronavirus-vaccine-trial-aims-to-have-500-people-in-testing-by-mid-may/

Virus Vaccine May Be Ready for Mass Production By Autumn, Oxford Professor Says

https://www.bloomberg.com/news/articles/2020-04-17/oxford-vaccine-veteran-lays-out-coronavirus-immunization-plans?utm_campaign=socialflow-organic&utm_source=twitter&cmpid=socialflow-twitter-business&utm_medium=social&utm_content=business

Good luck and GOD bless,

[georgejjl]

The COVID 19 trial with ChAdOx1 nCov-19

https://clinicaltrials.gov/ct2/show/NCT04324606

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-joins-consortium-rapidly-develop-covid-19-vaccine

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/OXB/14495849.html
Good luck and GOD bless,

[marcusl2]

https://www.edisongroup.com/wp-content/uploads/2020/04/Oxford-BioMedica-Juno-deal-expands-CAR-T-revenue-streams.pdf

[georgejjl]

Oxford Biomedica joins Consortium to rapidly develop a COVID-19 vaccine candidate
Consortium led by Jenner Institute, University of Oxford
Fast-tracked clinical trial of ChAdOx1 nCOV-19 vaccine candidate starts this month

Oxford, UK – 8th April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today it has joined a Consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine candidate for COVID-19, called ChAdOx1 nCov-19. This vaccine candidate is one of the leading vaccine candidates currently in development globally, and is expected to be the UK’s first COVID-19 vaccine in clinical trials later this month. The Consortium is led by the Jenner Institute, University of Oxford and also includes the Vaccines Manufacturing and Innovation Centre (VMIC), Pall Life Sciences, Cobra Biologics and Halix BV.

The Jenner Institute and the Oxford Vaccine Group have recruited individuals aged 18-55 from the Thames Valley area in the UK to study the vaccine’s safety and efficacy (see https://www.covid19vaccinetrial.co.uk/). Oxford Biomedica will provide access to its large scale GMP manufacturing facilities for viral vectors, including its new Oxbox facility, to the Consortium as required, which, along with other Consortium manufacturing partners in the UK and internationally, would allow for scaled manufacturing capacity should the safety and efficacy of the vaccine candidate be confirmed in clinical trials.

The Oxford vaccine candidate relies on adenoviral vector technology, ChAdOx1, developed at the Jenner Institute, in Oxford. It is seen as one of the most promising vaccine technologies for COVID-19 as ChAdOx1 has been shown to generate a strong immune response from one dose and it has demonstrated a good safety profile in pre-clinical and clinical trials conducted to date. No financial terms were disclosed.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “As an established clinical and commercial manufacturer of viral vectors, we are very pleased to be in a strong position in terms of capacity and capabilities to support the important and urgent efforts of the Consortium led by the Jenner Institute, University of Oxford, to develop and scale up manufacturing of this promising vaccine candidate for COVID-19.

“While our current activities on this vaccine candidate are just initiating, should the Consortium confirm there is promise for this candidate in the clinical trial initiating this month, we will play our role within the Consortium to scale up manufacturing as fast as possible. This will help to provide significant access to the vaccine candidate for further clinical trials and potentially, if approved for use, for many people in the UK and beyond.”

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-joins-consortium-rapidly-develop-covid-19-vaccine

Good luck and GOD bless,

[georgejjl]

AXO-Lenti-PD

http://investors.axovant.com/static-files/986b7b10-3d28-4afc-947b-bd959d9a9732

Good luck and GOD bless,

[marcusl2]

AXO-Lenti-PD delivers a 22-point (44%) improvement from baseline in the second dose cohort at 6 months

$65 million offering is expected to close on February 24, 2020


HTTps://synthace.com/lp-oxb-webinar-feb20
@markusgershater
Biologist who aspires to engineer. CSO & cofounder
@synthace

I've just had a sneak preview of what Tom Evans and André Raposo from
@OxfordBiomedica
are going to present at next week's webinar. Truly blown away by the science they're doing with Antha.

[georgejjl]

British scientists accidentally discover immune cell that 'may kill all cancer'

https://www.theblaze.com/news/immune-cell-may-cure-all-cancer

Good luck and GOD bless,

[georgejjl]

Harnessing the immune system to fight cancer could treat ‘all forms of the disease’

https://www.yahoo.com/lifestyle/harnessing-the-immune-system-to-fight-cancer-could-treat-all-forms-of-the-disease-115210272.html

Good luck and GOD bless,

[georgejjl]

Immune discovery 'may treat all cancer'

https://www.bbc.com/news/health-51182451

Good luck and GOD bless,

[georgejjl]

Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis.
Badin RA1,2, Binley K3, Van Camp N1,2, Jan C1,2, Gourlay J1,2, Robert C1,2, Gipchtein P1,2, Fayard A1,2, Stewart H3, Ralph GS3, Lad Y3, Kelleher M3, Loader J3, Hosomi K4,5, Palfi S4,5, Mitrophanous KA3, Hantraye P1,2.
Author information
1
CEA, DRF, Institute of Biology François Jacob, Molecular Imaging Research Center (MIRCen), 92265 Fontenay-aux-Roses, France.
2
CNRS, CEA, Paris-Sud University, Université Paris-Saclay, Neurodegenerative Diseases Laboratory (UMR9199), 92265 Fontenay-aux-Roses, France.
3
Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, UK.
4
AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, Neurochirurgie, Créteil, 94010, France.
5
Université Paris 12, Faculté de Médecine, IMRB, INSERM U955, Team 14, Créteil 94010, France.
Abstract
A recent phase I-II, open-label trial of ProSavin, a lentiviral vector delivering the key enzymes in the dopamine biosynthetic pathway to non-dopaminergic striatal neurons, demonstrated safety and improved motor function in parkinsonian patients. However, the magnitude of the effect suggested that optimal levels of dopamine replacement may not have been achieved. OXB-102, a lentiviral vector with an optimized expression cassette for dopamine biosynthesis, has been shown to achieve a significantly higher dopamine yield than ProSavin. We assessed the efficacy of OXB-102 in the MPTP macaque model of Parkinson's disease (PD). At 6 months post-vector administration, all treated animals showed significant improvements in clinical scores and spontaneous locomotor activity compared to controls, with the highest recovery observed in the OXB-102 high-dose (HD) group. Positron emission tomography quantification of 6-[18F]-fluoro-L-m-tyrosine uptake showed a significant increase in amino acid decarboxylase activity for all treated animals, compared with controls, where the OXB-102 HD group showed the highest level of dopaminergic activity. A toxicology study in macaques demonstrated that the vector was safe and well tolerated, with no associated clinical or behavioral abnormalities and no immune response mounted against any transgene products. Overall, these data support the further clinical development of OXB-102 for the treatment of PD.

Full paper at the link below:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685641/

Good luck and GOD bless,

[marcusl2]

https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers-gene-therapy

[marcusl2]

Oxford Biomedica PLC
19 December 2019
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors
Oxford, UK - 19 December 2019: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products. This builds on the existing three year commercial supply agreement signed by the parties in July 2017.
Under the terms of the Agreement, Oxford Biomedica will receive a minimum $75 million from Novartis over the next five years in manufacturing revenue with additional undisclosed process development fees. A mid single digit GBPm payment will also be paid in the medium term as a facility reservation fee with other terms such as royalties on net sales of resulting CAR-T products as previously agreed in 2014.
Oxford Biomedica will dedicate a manufacturing facility to Novartis within its new 7,800m(2) commercial manufacturing centre OxBox, in Oxford, UK. Oxford Biomedica will also be responsible for ensuring that at least two of its GMP facilities are capable of commercial supply for Novartis' CAR-T progammes.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: "This five year extension to our commercial supply agreement with Novartis for the LentiVector(R) platform is testament to the joint success achieved in this strategically important collaboration since 2013. This closely integrated collaboration with Novartis underlines the long-term committment both companies have made to manufacturing CAR-T therapies.
"This is also the first long-term commitment of a partner to reserve a dedicated GMP facility in our new OxBox GMP facility, which we expect to become operational in early 2020. While stable and long-term supply of lentiviral vectors for commercial CAR-T products is key to both companies, we are also pleased to announce that we are now working on five different lentiviral vectors for CAR-T products in the Novartis portfolio and we look forward to helping Novartis to innovate in this exciting therapeutic space".